FiercePharmaAsia—U.S.-China trade war; Takeda’s Alunbrig beats Xalkori; FDA scolds Huahai

The U.S.-China trade war, Takeda's Alunbrig and Zhejiang Huahai made our news this week. (Google)

After the latest round of tariff war escalation, nearly all U.S. medtech exports to China are now subject to additional tariffs. Takeda's Alunbrig triumphed over Pfizer's Xalkori in a head-to-head first-line ALK-positive lung cancer trial. The U.S. FDA criticized Zhejiang Huahai Pharmaceutical, which is linked to the global valsartan recall, for making manufacturing process changes without formal evaluation. And more.—Angus Liu

1. Trade war tariffs now touch nearly every U.S. medical device sold in China